Navigation Links
Concomitant use of Perforomist & tiotropium -- significant improvements -- COPD
Date:5/20/2008

Napa, CA (May 20, 2008) Data presented today at the International Conference of the American Thoracic Society (ATS) demonstrate that concomitant therapy with Perforomist Inhalation Solution (formoterol fumarate inhalation solution; FFIS), delivered by nebulization, and Spiriva (tiotropium; TIO) is significantly more effective than treatment with tiotropium alone.

Perforomist Inhalation Solution was approved in 2007 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is the only FDA-approved nebulized formoterol fumarate.

Donald P. Tashkin, MD, FACP, FCCP, Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles and lead clinical investigator, presented the results from Addition of Nebulized Formoterol Fumarate to Tiotropium Treatment Relieves Dyspnea and Symptoms in COPD Patients in a poster session today.

In this study there was a significant improvement in patients treated concomitantly with Perforomist nebulized formoterol fumarate and tiotropium over tiotropium alone, said Dr. Tashkin. These data provide physicians with a new and valuable treatment option for COPD patients with moderate to severe manifestations of the disease.

This randomized, placebo-controlled double-blind trial was conducted in 130 patients with moderate to severe COPD to evaluate the efficacy and safety of Perforomist, nebulized FFIS, when added to Spiriva maintenance treatment. Patient-centered outcomes were measured by the baseline/transitional dyspnea index, daily recording of COPD symptoms, rescue albuterol use and St. Georges Respiratory Questionnaire (SGRQ).

In this trial there was a statistical significance between the mean transitional dyspnea index scores in the Perforomist/TIO and TIO/placebo groups (2.30 and 0.16, respectively; p=0.0002). Shortness of breath, chest tightness, nighttime awakenings, and total symptom scores all improved significantly with the Perforomist/TIO treatment compared with TIO/placebo (p<0.05). Cough scores did not differ between groups. Albuterol use declined in the Perforomist/TIO group from 2.4 to1.3 puffs/day and increased in the TIO/placebo group from 2.8 to 3.4 puffs/day over six weeks; another statistically significant difference (p< 0.0001). SGRQ total scores did not change markedly from baseline or differ between groups except for the symptom domain score, which was superior in the Perforomist/TIO group compared to TIO/placebo (-6.3, p<0.04).

DEY is very pleased with the results of this study and the benefit that patients are seeing with Perforomist Inhalation Solution, said Carolyn Myers, Ph.D., President of Dey, L.P. We wish to thank Dr. Tashkin and the other members of the research team for their careful investigation into the clinical benefits of concomitant therapy of Perforomist and tiotropium. At DEY, we are committed to developing effective new treatments for serious and complex diseases, and with Perforomist are proud to provide physicians and patients a twice-daily COPD maintenance medication that offers the flexibility of dosing via nebulization.

For those attending ATS 2008, the presentation is available as follows:

Poster viewing: Session ID C42 COPD Pharmacotherapy I: Effects of Bronchodilators Tuesday, May 20, 2008, 10:45 a.m. 12:30 p.m. EDT Metro Toronto Convention Center; Area F: Halls A-B North Building, Level 300

Poster # F4: Addition of Nebulized Formoterol Fumarate to Tiotropium Treatment Relieves Dyspnea and Symptoms in COPD Patients


'/>"/>

Contact: Amy Techtmann
amy.techtmann@fkhealth.com
617-761-6784
Feinstein Kean Healthcare
Source:Eurekalert

Related medicine news :

1. Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD
2. Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
3. Perforomist-comparable pharmacokinetic and pharmacodynamic profile to DPI formulation
4. Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008
5. International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam
6. Riley Hospital for Children & Capital Institute of Pediatrics become international sister hospitals
7. IU Health & Wellness: New research findings from the Kinsey Institute
8. European Society of Human Reproduction & Embryology 24th annual meeting
9. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
10. IU Health & Wellness: Research and insights from Indiana University
11. Congressional R&D Caucus co-chairs join scientists, engineers and graduate students
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... ... pharmaceutical inserts and outserts. As a means of expanding capabilities Flottman has ... enable Flottman to individually code professional inserts (PIs) and patient package inserts (PPIs) ...
(Date:12/9/2016)... York, NY (PRWEB) , ... December 09, 2016 , ... ... raises awareness for organ transplantation while encouraging readers to sign up as an organ ... a lifesaving organ transplant. , An organ donor can save up to 8 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... will become Quality Insights beginning January 1, 2017. The name change aligns ... commitment to measuring and improving health care quality. , “We are very proud ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The ... ultimate weight loss and wellness program, at their world headquarters of Omni La Costa ... and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, or ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research and Markets ... Report" report to their offering. ... This report analyzes the worldwide markets for ... US, Canada , Japan , ... , and Rest of World. Annual estimates and forecasts are provided ...
(Date:12/8/2016)... 2016 Bodycad announced it has been ... accuracy, reproducibility and speed for 3D constructs via ... bone orthopaedic applications. These patents are critical to ... restorations based on each patient,s distinct anatomy. ... harnesses the world,s first suite of orthopaedic CAD/CAM ...
(Date:12/8/2016)... , Dec. 8, 2016 True Health ... brings leading-edge laboratory services and management expertise to ... , allowing more doctors and patients to ... management solutions. Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... Hospital systems, under pressure to contain costs, have ...
Breaking Medicine Technology: